HeraMED Limited Total Liabilities

Latest as of December 2025: €559.96K EUR ≈ $654.65K USD

HeraMED Limited total liabilities. Based on the latest financial reports, HeraMED Limited (1I4) has total liabilities worth €559.96K EUR (≈ $654.65K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See HeraMED Limited (1I4) liquidity interval to measure how many days the company can operate on defensive assets alone.

Total Liabilities of HeraMED Limited (2018–2025)

Total liabilities of HeraMED Limited from 2018 to 2025. This chart illustrates how HeraMED Limited's total liabilities have evolved over time, based on quarterly financial data. Explore 1I4 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

HeraMED Limited Competitors by Total Liabilities

The table below lists competitors of HeraMED Limited ranked by their total liabilities.

Company Country Total Liabilities
SPARK VC S.A. ZY 10
F:8N2
Germany €1.72 Million
Jembo Cable Company Tbk
JK:JECC
Indonesia Rp1.66 Trillion
Duksung
KO:004830
Korea ₩64.30 Billion
ENVIONEER Co.Ltd
KQ:317870
Korea ₩46.94 Billion
Central Petroleum Ltd
AU:CTP
Australia AU$69.56 Million
Eskay Mining Corp
V:ESK
Canada CA$907.11K
Enertork Ltd
KQ:019990
Korea ₩7.32 Billion
Farmer Bros. Co
NASDAQ:FARM
USA $118.78 Million

Liability Composition Analysis (2018–2025)

This chart breaks down HeraMED Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see HeraMED Limited (1I4) total assets.

Liquidity & Leverage Metrics

HeraMED Limited Total Liabilities Ratios Explained

HeraMED Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 4.49 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.60 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.38 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how HeraMED Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for HeraMED Limited (2018–2025)

The table below shows the annual total liabilities of HeraMED Limited from 2018 to 2025.

Year Total Liabilities Change
2025-12-31 €559.96K
≈ $654.65K
-67.31%
2024-12-31 €1.71 Million
≈ $2.00 Million
-36.90%
2023-12-31 €2.71 Million
≈ $3.17 Million
+42.61%
2022-12-31 €1.90 Million
≈ $2.23 Million
-59.45%
2021-12-31 €4.70 Million
≈ $5.49 Million
+202.34%
2020-12-31 €1.55 Million
≈ $1.82 Million
-10.53%
2019-12-31 €1.74 Million
≈ $2.03 Million
+3.38%
2018-12-31 €1.68 Million
≈ $1.96 Million
--

About HeraMED Limited

F:1I4 Germany Medical Devices
Market Cap
$27.68 Million
€23.68 Million EUR
Market Cap Rank
#23891 Global
#2077 in Germany
Share Price
€0.02
Change (1 day)
-19.61%
52-Week Range
€0.02 - €0.03
All Time High
€0.03
About

HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a digital maternity and women's health platform that focuses on improving clinical outcomes while supporting more effic… Read more